• 1
    Conti F, Morelon E, Calmus Y. Immunosuppressive therapy in liver transplantation. J Hepatol 2003;39:664-678.
  • 2
    Trunečka P, Boillot O, Seehofer D, Pinna AD, Fischer L, Ericzon BG, et al.; for Tacrolimus Prolonged Release Liver Study Group. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant 2010;10:2313-2323.
  • 3
    Florman S, Alloway R, Kalayoglu M, Lake K, Bak T, Klein A, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005;37:1211-1213.
  • 4
    Florman S, Alloway R, Kalayoglu M, Punch J, Bak T, Melancon J, et al. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation 2007;83:1639-1642.
  • 5
    Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology 2000;31:792-799.
  • 6
    Florman S. Tacrolimus once-daily formulation in the prophylaxis of transplant rejection in renal or liver allograft recipients: a viewpoint by Sander Florman. Drugs 2007;67:1944.
  • 7
    Fischer L, Trunečka P, Gridelli B, Roy A, Vitale A, Valdivieso A, et al. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. Liver Transpl 2011;17:167-177.
  • 8
    Dopazo C, Rodriguez R, Llado L, Calatayud D, Castells L, Ramos E, et al. Successful conversion from twice-daily to once-daily tacrolimus in liver transplantation: observational multicenter study. Clin Transplant 2012;26:E32-E37.
  • 9
    Sańko-Resmer J, Boillot O, Wolf P, Thorburn D. Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. Transpl Int 2012;25:283-293.
  • 10
    Mor E, Gonwa TA, Husberg BS, Goldstein RM, Klintmalm GB. Late-onset acute rejection in orthotopic liver transplantation—associated risk factors and outcome. Transplantation 1992;54:821-824.
  • 11
    Berlakovich GA, Langer F, Freundorfer E, Windhager T, Rockenschaub S, Sporn E, et al. General compliance after liver transplantation for alcoholic cirrhosis. Transpl Int 2000;13:129-135.
  • 12
    O'Carroll RE, McGregor LM, Swanson V, Masterton G, Hayes PC. Adherence to medication after liver transplantation in Scotland: a pilot study. Liver Transpl 2006;12:1862-1868.
  • 13
    Stilley CS, DiMartini AF, de Vera ME, Flynn WB, King J, Sereika S, et al. Individual and environmental correlates and predictors of early adherence and outcomes after liver transplantation. Prog Transplant 2010;20:58-66.
  • 14
    Sabate E, ed. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
  • 15
    Dharancy S, Giral M, Tetaz R, Fatras M, Dubel L, Pageaux GP. Adherence with immunosuppressive treatment after transplantation: results from the French trial PREDICT. Clin Transplant 2012;26:E293-E299.
  • 16
    Burra P, Germani G, Gnoato F, Lazzaro S, Russo FP, Cillo U, Senzolo M. Adherence in liver transplant recipients. Liver Transpl 2011;17:760-770.
  • 17
    Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-2335.